Increased IL-12 and decreased IL-33 serum levels are associated with increased Th1 and suppressed Th2 cytokine profile in patients with diabetic nephropathy (CURES-134)

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 11, 2014, Pages 8008-8015

  Anand, Gowrishankar ^a   Vasanthakumar, Rathinam ^b   Mohan, Vishwanathan ^c   Babu, Subash ^d   Aravindhan, Vivekanandhan ^a,e  

^a ANNA UNIVERSITY   (India)

^b PRATHYUSHA ENGINEERING COLLEGE   (India)

^c MADRAS DIABETES RESEARCH FOUNDATION   (India)

^d National Institutes of Health International Center for Excellence in Research   (India)

^e UNIVERSITY OF MADRAS   (India)

Author keywords

Diabetic nephropathy; IFN ; IL 12; IL 13; IL 2; IL 33; IL 4; IL 5

Indexed keywords

CYTOKINE; IL33 PROTEIN, HUMAN; INTERLEUKIN 12; INTERLEUKIN 33; INTERLEUKIN DERIVATIVE;

ADULT; AGED; BLOOD; DIABETIC NEPHROPATHY; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; TH1 CELL; TH2 CELL;

ADULT; AGED; CYTOKINES; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; INTERLEUKIN-12; INTERLEUKIN-33; INTERLEUKINS; MALE; MIDDLE AGED; TH1 CELLS; TH2 CELLS;

EID: 84919470636     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Striker GE, Agodoa LL, Held P, Doi T, Conti F and Striker LJ. Kidney disease of diabetes mellitus (diabetic nephropathy): perspectives in the United States. J Diabet Complications 1991; 5: 51-52.
2. Navarro-Gonzalez JF and Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008; 19: 433-442.
3. Mora C and Navarro JF. Inflammation and diabetic nephropathy. Curr Diab Rep 2006; 6: 463-468.
4. Heilbronn LK and Campbell LV. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr Pharm Des 2008; 14: 1225-1230.
5. Shikata K and Makino H. Role of macrophages in the pathogenesis of diabetic nephropathy. Contrib Nephrol 2001; 46-54.
6. Wu CC, Sytwu HK, Lu KC and Lin YF. Role of T cells in type 2 diabetic nephropathy. Exp Diabetes Res 2011; 2011: 514738.
7. Kelly KJ, Liu Y, Zhang J, Goswami C, Lin H and Dominguez JH. Comprehensive genomic profiling in diabetic nephropathy reveals the predominance of proinflammatory pathways. Physiol Genomics 2013; 45: 710-719.
8. Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, Lee J, Goldfine AB, Benoist C, Shoelson S and Mathis D. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 2009; 15: 930-939.
9. Galkina E and Ley K. Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol 2006; 17: 368-377.
10. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF and Kastelein RA. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23: 479-490.
11. Zeyda M, Wernly B, Demyanets S, Kaun C, Hammerle M, Hantusch B, Schranz M, Neuhofer A, Itariu BK, Keck M, Prager G, Wojta J and Stulnig TM. Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue. Int J Obes (Lond) 2013; 37: 658-665.
12. Hasan A, Al-Ghimlas F, Warsame S, Al-Hubail A, Ahmad R, Bennakhi A, Al-Arouj M, Behbehani K, Dehbi M and Dermime S. IL-33 is negatively associated with the BMI and confers a protective lipid/metabolic profile in non-diabetic but not diabetic subjects. BMC Immunol 2014; 15: 19.
13. Caner S, Usluogullari CA, Balkan F, Buyukcam F, Kaya C, Sacikara M, Koca C, Ersoy R and Cakir B. Is IL-33 useful to detect early stage of renal failure? Ren Fail 2014; 36: 78-80.
14. Deepa M, Pradeepa R, Rema M, Mohan A, Deepa R, Shanthirani S and Mohan V. The Chennai Urban Rural Epidemiology Study (CURES)--study design and methodology (urban component) (CURES-I). J Assoc Physicians India 2003; 51: 863-870.
15. Madhumitha H, Mohan V, Deepa M, Babu S and Aravindhan V. Increased Th1 and suppressed Th2 serum cytokine levels in subjects with diabetic coronary artery disease. Cardiovasc Diabetol 2014; 13: 1.
16. Unnikrishnan RI, Rema M, Pradeepa R, Deepa M, Shanthirani CS, Deepa R and Mohan V. Prevalence and risk factors of diabetic nephropathy in an urban South Indian population: the Chennai Urban Rural Epidemiology Study (CURES 45). Diabetes Care 2007; 30: 2019-2024.
17. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T and Coresh J. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
18. Navarro JF and Mora C. Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy. ScientificWorldJournal 2006; 6: 908-917.
19. Moon JY, Jeong KH, Lee TW, Ihm CG, Lim SJ and Lee SH. Aberrant recruitment and activation of T cells in diabetic nephropathy. Am J Nephrol 2012; 35: 164-174.
20. Surendar J, Mohan V, Rao MM, Babu S and Aravindhan V. Increased levels of both Th1 and Th2 cytokines in subjects with metabolic syndrome (CURES-103). Diabetes Technol Ther 2011; 13: 477-482.
21. Pacifico L, Di Renzo L, Anania C, Osborn JF, Ippoliti F, Schiavo E and Chiesa C. Increased T-helper interferon-gamma-secreting cells in obese children. Eur J Endocrinol 2006; 154: 691-697.
22. Kintscher U, Hartge M, Hess K, Foryst-Ludwig A, Clemenz M, Wabitsch M, Fischer-Posovszky P, Barth TF, Dragun D, Skurk T, Hauner H, Bluher M, Unger T, Wolf AM, Knippschild U, Hombach V and Marx N. T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol 2008; 28: 1304-1310.
23. Winer S, Chan Y, Paltser G, Truong D, Tsui H, Bahrami J, Dorfman R, Wang Y, Zielenski J, Mastronardi F, Maezawa Y, Drucker DJ, Engleman E, Winer D and Dosch HM. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med 2009; 15: 921-929.
24. Mishra M, Kumar H, Bajpai S, Singh RK and Tripathi K. Level of serum IL-12 and its correlation with endothelial dysfunction, insulin resistance, proinflammatory cytokines and lipid profile in newly diagnosed type 2 diabetes. Diabetes Res Clin Pract 94: 255-261.
25. Suarez-Alvarez K, Solis-Lozano L, Leon-Cabrera S, Gonzalez-Chavez A, Gomez-Hernandez G, Quinones-Alvarez MS, Serralde-Zuniga AE, Hernandez-Ruiz J, Ramirez-Velasquez J, Galindo- Gonzalez FJ, Zavala-Castillo JC, De Leon-Nava MA, Robles-Diaz G and Escobedo G. Serum IL-12 is increased in Mexican obese subjects and associated with low-grade inflammation and obesity-related parameters. Mediators Inflamm 2013: 967067.
26. Jiang LQ, Franck N, Egan B, Sjogren RJ, Katayama M, Duque-Guimaraes D, Arner P, Zierath JR and Krook A. Autocrine role of interleukin- 13 on skeletal muscle glucose metabolism in Type 2 diabetic patients involves microRNA let-7. Am J Physiol Endocrinol Metab 2013; 305: E1359-66.
27. Chang YH, Ho KT, Lu SH, Huang CN and Shiau MY. Regulation of glucose/lipid metabolism and insulin sensitivity by interleukin-4. Int J Obes (Lond) 2011; 36: 993-998.
28. Dronavalli S, Duka I and Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab 2008; 4: 444-452.
29. Wu CC, Chen JS, Lu KC, Chen CC, Lin SH, Chu P, Sytwu HK and Lin YF. Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy. Clin Chim Acta 2010; 411: 700-704.
30. Bending JJ, Lobo-Yeo A, Vergani D and Viberti GC. Proteinuria and activated T-lymphocytes in diabetic nephropathy. Diabetes 1988; 37: 507-511.